On I-Hub it was clear that the company's contract
Post# of 15624
(Total Views: 443)
Posted On: 05/04/2017 11:01:08 PM
On I-Hub it was clear that the company's contract with Medmar has been cancelled, and the $300K has been repaid to them. I believe in the long run this will result in substantially higher income from U.S. sales, but right now it's causing the stock's weakness as they've not yet provided a plan for replacing Medmar for U.S. sales.
Barring an agreement with someone who can hit the deck running, I believe it's doubtful that U.S. sales won't be delayed by at least a couple months.
One question that eventually will be answered by results of the Phase 1 Safety Trials is, have any side effects been found that would limit the use of the product. If the answer to this question is NO, the next question might be, does a company like Emilia look at what it would take to market this product everywhere in the U.S., not just in medical marijuana states.
I'm not suggesting this will happen, but if no side effect can be found from the cannabis component, other than the skin diseases get better, why shouldn't this be treated as a cosmetic product, ignoring the effective ingredient is cannabis based.
I don't expect this to happen, but some day we may get there. For now, I believe the company needs to provide us with a plan of action for U.S. sales, as well as confirmation of when sales will begin elsewhere. If the announcement on how Medmar is to be replaced is well received by investor's, I believe the price will quickly exceed a dollar and grow from there.
Gary
Barring an agreement with someone who can hit the deck running, I believe it's doubtful that U.S. sales won't be delayed by at least a couple months.
One question that eventually will be answered by results of the Phase 1 Safety Trials is, have any side effects been found that would limit the use of the product. If the answer to this question is NO, the next question might be, does a company like Emilia look at what it would take to market this product everywhere in the U.S., not just in medical marijuana states.
I'm not suggesting this will happen, but if no side effect can be found from the cannabis component, other than the skin diseases get better, why shouldn't this be treated as a cosmetic product, ignoring the effective ingredient is cannabis based.
I don't expect this to happen, but some day we may get there. For now, I believe the company needs to provide us with a plan of action for U.S. sales, as well as confirmation of when sales will begin elsewhere. If the announcement on how Medmar is to be replaced is well received by investor's, I believe the price will quickly exceed a dollar and grow from there.
Gary
(2)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼